Stephen T Warren, Ph.D., FACMG
|
Biography Dr. Stephen T. Warren received his PhD in Human Genetics from Michigan
State University in 1981 and from 1981 to 1985 was a fellow at the
University of Illinois College of Medicine. In 1984, Dr. Warren also
was a visiting scientist at the European Molecular Biology Laboratory
in Heidelberg. In 1985 he joined the faculty of Emory University School
of Medicine as an Assistant Professor of Biochemistry and of
Pediatrics. Currently Dr. Warren holds the William Patterson Timmie
Professorship of Human Genetics at Emory, and is also Professor of
Biochemistry, Professor of Pediatrics and Professor in the Winship
Cancer Institute. In 1991 Dr. Warren was named an Associate
Investigator of the Howard Hughes Medical Institute and was promoted to
Full Investigator in 1995. In January 2001 Dr. Warren founded, as
chairman, the Department of Human Genetics at Emory School of Medicine.
Dr. Warren is a Diplomat of the American Board of Medical Genetics with
specialty certification in both clinical cytogenetics and clinical
molecular genetics. He is a founding Fellow of the American College of
Medical Genetics and a member of the Human Genome Organization. Dr.
Warren has held various committee memberships in the American Society
of Human Genetics. He was elected to the Board of Directors in 1997 and served as President in 2006. He serves, or has served, on the
editorial boards of the major journals in human genetics and is the
past chairman of the NIH Mammalian Genetics Study Section and of the
NIGMS Working Group on the Human Genetic Mutant Cell Repository. Dr. Warren has served on the NIMH Council and currently serves on the NIMH Board of Scientific Counselors. From 1999 until 2005, Dr. Warren was Editor-in-Chief of The American Journal of
Human Genetics. Among his awards are the Albert E. Levy Faculty Award
from Emory University, the inaugural William Rosen Research Award from
the National Fragile X Foundation, and a MERIT award from the National
Institute of Health. In 1999, Dr. Warren was awarded the William Allan
Award from the American Society of Human Genetics for his research on fragile X
syndrome. In 2003, he was an inaugural inductee of the National
Institute of Child Health and Human Development's Hall of Honor. In 2004, Dr. Warren was elected to the Institute of Medicine
of the National Academies, considered one of the highest honors in the
fields of medicine and health. In 2006, he won the William Rosen Research Award for the second time from the National Fragile X Foundation. In 2007, he was won the Michigan State University Outstanding Alumni Award. In 2008 he won both the Brandwein Award in Genetic Research and the "Champion for Babies" award from the March of Dimes. In 2009, Dr. Warren won the Jacob's Ladder International Research Prize and the American Academy of Neurology "Frontiers in Clinical Neuroscience" award.
Research Description Mental retardation (MR) represents a deficiency in
cognition, limiting adaptive behavior that is normally reflected in
maturation, learning, or social adjustment. Approximately 3 percent of
the population are mentally retarded, with IQ levels of less than 68.
It has been recognized for almost a century that significantly more
males than females are affected. Explanations have varied, but the
reason most widely accepted today is genetic. It has been suggested
that certain X-linked genes, when mutated, may result in MR and that
females are protected by having two X chromosomes, unlike males, who
have only one.
Numerous pedigrees reflecting
this typical X-linked pattern of inheritance of MR have been described.
Since patients seldom exhibit an obvious phenotype other than MR, they
were grouped together as having nonspecific X-linked MR. Their
condition, it was believed, was due to any number of X-linked
mutations, each relatively rare. Work beginning in the early 1970s
began to elucidate a single mutation among many families with
nonspecific X-linked MR. This mutation causes what is now known as
fragile X syndrome. It accounts for almost half of all nonspecific
X-linked MR and, indeed, is the commonest form of inherited MR. Fragile
X is named for a gap, observed on the X chromosomes of affected
patients, that appears fragile when viewed under the microscope. Over
the past decade our laboratory has been studying fragile X syndrome and
in 1991, working with an international group of collaborators, we
identified the FMR1 (fragile X mental retardation 1) gene, which is
responsible for this syndrome.
Within the 5'
untranslated portion of the FMR1 mRNA is an unusual tract of the
repeated triplet CGG. Among normal individuals, this triplet repeat is
polymorphic in length and content, with 7-52 triplets (mean of 30),
often containing 1-3 AGG interruptions of the CGG array. Individuals
with fragile X syndrome exhibit a massive expansion of this repeat
beyond 230 triplets, usually exceeding 700 repeats. Unaffected, carrier
males and many carrier females exhibit repeat lengths intermediate
between normal and affected. These intermediate-length alleles are
unstable when transmitted, tending to increase slightly in length. This
form of mutation, due to unstable trinucleotide repeats, had not been
previously observed in any other genetically studied organism. Since
the repeat expansion in fragile X syndrome was discovered in 1991, over
a dozen other genetic diseases have been attributed to this novel form
of mutation.
The mechanism behind the repeat
expansion for these disorders remains unknown. However, in fragile X
syndrome some clues have emerged. Polymorphic markers within and near
FMR1 can describe the regional "signature" of distinctive normal X
chromosomes haplotypes. We and others have shown that certain
haplotypes are more frequently found among fragile X chromosomes than
would be expected based on the haplotype occurrence on normal X
chromosomes. This is referred to as linkage disequilibrium and suggests
that fragile X syndrome occurs only in a limited number of X
chromosomes in the population.
When the CGG
repeat is longer than approximately 230 triplets, sequences of and
surrounding the repeat are concomitantly methylated. This abnormal
methylation indirectly attracts the enzyme histone deacetylase, which
alters the chromatin conformation of the FMR1 gene. The result is the
transcriptional silencing of FMR1, and the absence of FMR1 protein
(FMRP) is now accepted as the basis for the phenotype.
Much
of our current work has focused upon the biochemical and
neurobiological consequence of the loss of FMRP. We have previously
shown that FMRP contains sequence attributes of RNA-binding proteins
and indeed interacts with a subset of brain mRNA, even as a purified
protein. We have also identified two additional functional domains
within FMRPinvolving nuclear import and export of FMRPand have shown
FMRP shuttles between the nucleus and the cytoplasm and incorporates
into mRNP particles composed of other proteins and selective RNA
molecules. These particles are associated with ribosomes in the
cytoplasm of various cell types, including the somatodendritic
compartments of neurons.
The importance of the
association of FMRP with ribosomes is highlighted by our studies of an
atypical patient with a mutation that changes an amino acid within
FMRP. The mutant protein in this patient, who has unusually severe
fragile X syndrome, binds RNA but no longer associates with ribosomes.
We speculate that the mutant protein is sequestering the bound mRNAs,
preventing even minimal translation.
The next
major challenge in this research will be to identify those mRNAs that
interact with FMRP and examine the consequence of FMRP loss on their
translated proteins. We have identified several interacting messages by
using mRNA isolated from the immunoprecipitated mouse brain
Fmrp-containing mRNP complex, and interrogating some 40,000 genes on
microarrays. Moreover, many of these same messages show an altered
translational profile, which is the abundance of a message off or on
polyribosomes, in the absence of Fmrp. These data are consistent with
the model that the absence of FMRP may miscue translation of those
messages normally bound to FMRP. In neurons, this may influence
synaptic plasticity, as reflected by the delayed dendritic spine
maturation we and others have observed in the Fmr1 knockout mouse.
Understanding the function of these proteins could provide considerable
insight into the pathophysiology of this disorder and may well
illuminate molecular mechanisms important to human intelligence.
|